Loading
Everything OnCo dates to 1986: 16 entries, 8 landmarks, 4 journals founded, 1 approval and 1 company founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
16 dated entries in OnCo fall in 1986: 8 landmarks, 4 journals founded, 1 approval, 1 company founded, 1 paper and 1 technology.
Of those, 16 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Hairy cell leukaemia
The publication year on key paper records.
Dvorak HF. New England Journal of Medicine.
The history entries editors wrote on cancer records: the dated turning points of each disease.
High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)
Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma
Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)
HPV-associated vulvar squamous cell carcinoma
Prostate cancer
Osteosarcoma
Retinoblastoma. The first tumour-suppressor gene identified.
Colorectal cancer. Quirke sliced 52 rectal specimens transversely: 14 had tumour at the lateral margin and 12 of those recurred locally, which redefined recurrence as a problem of...
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Chicago, IL
The founded year on journal records.
Springer Nature
Taylor & Francis (Informa UK)
Springer Nature (Springer Medizin)
SAGE Publishing